MR MRNA Moderna Inc. Loading... : Bullish and Bearish Analyst Opinions

Jefferies raises its price target on Moderna shares to 60 dollars, providing a boost to the stock.

Moderna shares fell 11 percent in their worst single-day decline since May 2025.

Reports RSV vaccine revenue declining from $25m to $8m year-over-year; no directional view or thesis stated by speaker.

Moderna turnaround on new pipelines.

Promising cancer vaccines make Moderna investable again.

Moderna CEO Stephane Bancel said the pending flu vaccine launch could start a public conversation about mRNA technology offering better seasonal protection.

Moderna shares decline 7.4 percent following a near 40 percent surge over the past six trading sessions.

FDA advisory committee voted favorably on Moderna's flu vaccine benefit-risk profile, a regulatory milestone.

FDA advisory committee unanimously backs Moderna's MRNA-1010 seasonal flu vaccine with PDUFA goal date remaining August 5, 2026.

FDA advisory committee voted unanimously in favor of Moderna's MRNA-1010 seasonal flu vaccine with PDUFA goal date remaining August 5 2026.

Moderna's mRNA-based influenza vaccine received a recommendation for approval from FDA outside advisers, marking a positive development for the contentious product.

FDA staff report scrutinizes evidence supporting Moderna's flu vaccine ahead of advisory committee meeting.

Moderna secures a 50 million dollar contract from an unnamed source for its Ebola vaccine development program.

Long MRNA via calls as a virus/pandemic hedge play.

MRNA yolo virus-hedge call position.

Long $MRNA via calls — speaker bought MRNA calls Thursday as hedge on Hantavirus virus narrative; expects media to pump fear, Moderna has early-stage vaccine.

User pussinbuuts (+8) notes MRNA working on vaccines, with +12% Friday and +8% premarket momentum. Vaccine‑themed stocks can sustain momentum on pandemic fears and low‑rate printing environment (as Nudge55 mentions). Ride the momentum long on MRNA for continued vaccine‑related gains. News‑driven move may fade quickly; low conviction (only one proponent).

Bought MRNA calls Thursday, already up over 100% — yolo play, could go 1000% or to zero.

Yolo calls on MRNA — up over 100% in 2 days.

Bitcoinduke questions whether Moderna stock is about to rally, implying skepticism about a potential pump in the biotech name.

Owns Moderna calls that are up but speaker himself isn't, confirming active long calls position.

Moderna shares are being discussed in a reply thread on social media platform X with a link to additional content.

The author expresses surprise at Moderna's strong price movement but admits they did not take a large position, offering no forward-looking opinion.

Long $MRNA via calls — speaker confirms active MRNA call position, up 108% intraday on yesterday's purchase.

Holds MRNA calls, awaiting them to hit — confirms active long calls position.

Seeking Alpha highlights Stephen Ayers' bearish view that Moderna's mRESVIA is struggling against entrenched rivals Pfizer and GSK, with waning efficacy and a limited market dimming its blockbuster potential.

A comment notes that Moderna started working on a hantavirus vaccine two years prior, and a cruise ship outbreak is now in the news. The WHO has put the chance of a new hantavirus pandemic at 10% (mentioned in another upvoted comment). If the hantavirus story gains traction, MRNA could spike as the only named player with a vaccine. This is a speculative, catalyst‑driven play. YOLO on MRNA – high risk/reward bet on pandemic panic and vaccine demand. The virus may remain contained; the 10% probability implies 90% chance nothing happens. MRNA stock has been volatile and could fade quickly.

Long $MRNA — speaker bought 150 MRNA $60 July strike calls to hedge on new virus narrative; Moderna has prior vaccine work.

A user claims “Insider told me MRNA is already working on a vaccine for hantavirus” (+7). This is a classic WSB rumor, but the thread is fixated on hantavirus news (multiple comments about outbreak in Europe, etc.). If the outbreak escalates, vaccine development hype could lift MRNA shares. The community is already treating it as a possible COVID-deja-vu play. A high-risk speculative long based on a joke rumor with real underlying fear. Could see short-term momentum on headlines. The comment is likely sarcastic; no confirmation. Hantavirus is not a new pandemic threat. MRNA may not actually be working on it. OIL (USO / CL) - LONG | confidence: 0.55 | sentiment: +0.50 Speaker: r/wallstreetbets community Thesis: A user notes “Man… oil prices below $100 didn’t last very long…” (+7), implying oil has bounced back and will stay elevated. Iran rejecting the proposal is bullish for crude (supply disruption risk). The market is pricing in geopolitical instability in the Strait of Hormuz. The community agrees that cheap oil was temporary. Long oil (via USO or futures) as a hedge against Middle East tensions. The sentiment aligns with the “deals never happen” skepticism. A surprise deal could crash oil. The Fed or global recession could also cap prices.

A +6 upvoted comment states Moderna has been working on a Hantavirus vaccine since July 2024, urging "time to buy stock." The thread also compares the virus to "the next Rona," implying a pandemic-like catalyst. If the Hantavirus scare escalates (even if sensationalized), vaccine developers like Moderna could see a rapid price spike, similar to the COVID-19 playbook. The comment is active and upvoted, indicating some community legitimacy. Speculative bet on a health crisis narrative. Buy MRNA for a short-term virus-driven pop. The virus may not become a major outbreak; Moderna’s vaccine is still early stage; the stock could gap down if news fizzles.